

VolitionRx

11:15 29 Apr 2020

VolitionRx welcomes proof of concept results as its Nu.Q assay detects two cancers common in dogs

VolitionRx Limited (NYSEAMERICAN:VNRX), the cancer diagnostics group, has moved a step closer to launching its first Nu.Q Vet product in the US as it unveiled positive results from its first proof of concept study.

The study was completed at the Texas A&M University (TAMU) and showed the test detected two cancers common in dogs.

READ: VolitionRx actively developing coronavirus (COVID-19) triage test using its proprietary Nu.QTM platform

At a specificity of 90%, a single Nu.Q Vet assay detected almost 70% of both Canine Hemangiosarcoma and Canine Lymphoma, the firm revealed. These two diseases represent a third of all canine cancers.

"It is exciting to see such strong results from our first Nu.Q™ Vet study conducted at Texas A&M University Veterinary Hospital," Dr Terry Kelly, the chief scientific officer of Volition America said in a statement.

"It is also interesting to note the similar patterns of detection seen in both canine and human samples confirming that the Nu.Q platform does appear to be useful in more than just human diagnostics.

"As with human diagnostics, there are currently no accurate, simple, affordable cancer screening tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage of their life. I look forward to completing the planned trials and to launch our first Nu.Q Vet product in the U.S. that we expect to occur in 2020."

Dr Heather Wilson-Robles, associate professor at TAMU and chief medical officer of Volition Veterinary Diagnostics, noted that the results had provided the firm with "confidence to move forward with other Vet assays" in the firm's pipeline, and with the larger range of cohorts and trials.

"Clearly, we still have work to do as this single assay did not detect one of the other top five canine cancers, Canine Osteosarcoma, which was the third cancer tested in this study. However, I am delighted to see such positive results in these two significant cancers and look forward to reporting further data over the coming quarters with additional Nu.Q™ Vet assays, this time tested on an automated platform," she said.


Volition's tests are based on the science of Nucleosomics, namely, the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition shares in New York nudged up 0.72% to \$4.20.

Price: 4.01

Market Cap: \$193.27 m

1 Year Share Price Graph



Share Information

Code: VNRX

Listing: NYSEMKT

52 week	High	Low
	5.2	2.22

Sector: Pharma & Biotech

Website: volitionrx.com

Company Synopsis:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

action@proactiveinvestors.com

Contact the author at giles@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).